1,4-Dioxa-8-azaspiro(4.5)decane → 1-[[2-(3,4,5-Trimethoxyphenyl)pyridin-4-yl]methyl]-4-piperidone ethylene ketal
反応式
[CH2:1]1[O:10][C:4]2([CH2:9][CH2:8][NH:7][CH2:6][CH2:5]2)[O:3][CH2:2]1.Cl[CH2:12][C:13]1[CH:18]=[CH:17][N:16]=[C:15]([C:19]2[CH:24]=[C:23]([O:25][CH3:26])[C:22]([O:27][CH3:28])=[C:21]([O:29][CH3:30])[CH:20]=2)[CH:14]=1>>[CH2:1]1[O:10][C:4]2([CH2:9][CH2:8][N:7]([CH2:12][C:13]3[CH:18]=[CH:17][N:16]=[C:15]([C:19]4[CH:24]=[C:23]([O:25][CH3:26])[C:22]([O:27][CH3:28])=[C:21]([O:29][CH3:30])[CH:20]=4)[CH:14]=3)[CH2:6][CH2:5]2)[O:3][CH2:2]1参加物
3
実験手順
4-Piperidone ethylene ketal (12.0 g) and 4-chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine (12.3 g) was condensed in the same manner as described in Example 2 to give the title compound.
後処理
- customcondensed in the same manner
出典と根拠
- ORDレコード
- ord-eaa019518e404ed68b2e57813a42b2af
- 出典データセット
- uspto-grants-2003_08